Creyon Bio Partners with Lilly to Accelerate AI-Designed RNA-Targeted Oligo Therapies for Rare and Common Diseases

SAN DIEGO—Creyon Bio, Inc. ("Creyon") has announced a significant global licensing and multi-target research collaboration with Eli Lilly and Company ("Lilly"). The partnership focuses on developing innovative RNA-targeted oligonucleotide (oligo) therapies for a variety of diseases, both rare and common. Creyon will utilize its cutting-edge AI-Powered Oligo Engineering Engine to design and optimize new drug candidates, aiming to achieve timelines that have traditionally been unattainable in nucleic acid drug development. Serge Messerlian, Chairman and CEO of Creyon Bio, expressed enthusiasm about the partnership, stating, “We are excited to join forces with Lilly to advance our AI-designed oligos. Our primary goal is to enhance the safety and efficacy of therapies for patients. This collaboration marks a crucial milestone as we move our RNA-targeted oligo therapy pipeline closer to clinical trials.” The uniqueness of Creyon's approach lies in its AI-Powered Oligo Engineering Engine. According to Swagatam Mukhopadhyay, Co-Founder and Chief Innovation Officer, “Creyon's engine uses quantum chemistry principles to systematically design RNA-targeted oligos, eliminating the need for labor-intensive and less reliable trial-and-error screening. This technology accelerates development timelines and ensures a more cost-effective process.” Financial details of the agreement include an upfront payment of $13 million to Creyon, comprising cash and equity purchases. Additionally, Creyon stands to receive over $1 billion in potential development and commercialization payments if specific milestones are met. Lilly will hold an exclusive license to each lead candidate identified through this collaboration and will be responsible for subsequent research, development, and commercialization efforts. About Creyon Bio, Inc. Creyon Bio is a pioneering nucleic acid drug development company dedicated to improving the safety and effectiveness of oligonucleotide therapies for patients suffering from a wide array of rare and common diseases. By merging advanced computational techniques with targeted, tissue-specific delivery methods, Creyon aims to create first-class, RNA-targeted oligo treatments. The company's proprietary AI-Powered Oligo Engineering Engine revolutionizes the design of oligos, offering a systematic and efficient alternative to conventional methods. For more information about Creyon Bio and their groundbreaking technologies,visit their website at www.creyonbio.com and follow them on LinkedIn and X. Creyon Bio continues to make headlines in the field of nucleic acid therapeutics, showcasing its commitment to advancing medical treatments through innovative technologies.